ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis 2Q Net Profit Up Marginally, Beating Expectations

By Marta Falconi ZURICH--Swiss drug maker Novartis AG (NVS) said Thursday its net profit rose slightly in the second quarter, helped by the good performance of its eye care unit and the flagship pharmaceutical division, which helped offset weaker sales of blockbuster drug Diovan, which was hurt by increased generics competition. The Basel-based company said it is on track to deliver 2012 full-year outlook after net profit for the three months to the end of June edged up to $2.71 billion from $2.70 billion in the same period a year earlier, above analysts' expectations of $2.52 billion. Net sales were down 4% at $14.3 billion, hurt by increased competition for the company's generic unit Sandoz and the continued drag from the suspension of production at a factory in Lincoln, Nebraska. Sales at the flagship pharmaceuticals division decreased 1% to $8.3 billion. Write to Marta Falconi at marta.falconi@dowjones.com Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=CH0012005267 or call +44 (0)208 391 6028 Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=US66987V1098 or call +44 (0)208 391 6028 Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Novartis (NVS)
DateTimeHeadline
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/17/201513:02:02Could This Be Healthcare's $158 Billion Black Swan Event?
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201515:04:02GlaxoSmithKline PLC Earnings: Pay No Attention to the Results...
05/08/201511:12:03The Best Fidelity Mutual Funds
05/07/201513:40:20Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/07/201513:34:24Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/06/201518:01:31ADR Shares End Mixed; Anheuser-Busch InBev Rises
05/06/201508:50:06GSK Cuts Return to Holders From Novartis Asset Swap
05/06/201507:58:20Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million
05/04/201519:22:23Generic Drugs Grab Growing Market Share in Mexico--Update
05/04/201519:22:11Generic Drugs Grab Market Share in Mexico
05/04/201511:57:01Why Shares in Array BioPharma, Inc. Are Soaring Higher
05/02/201510:41:02The Best Way to Invest Money in Silicon Valley
05/01/201514:49:19Waiting for Exelixis, Inc.'s Meteor to Land
04/30/201513:47:19Teva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays...
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad